In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hitachi Chemical Co. Ltd.

www.hitachichemical.com

Latest From Hitachi Chemical Co. Ltd.

Investment Outlook For Cell And Gene Therapies Is Cautiously Optimistic

Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.

Regenerative Medicine Financing

Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones

Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.

Commercial Deals

Berkeley HeartLab: Getting It Right the Second Time

One of the great mysteries that has long bewildered cardiologists is why as many people with normal cholesterol levels suffer from heart disease and sudden cardiac death as do those with elevated cholesterol. Building on technology developed at the Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley HeartLab has developed a battery of proprietary diagnostic tests that reveal cholesterol abnormalities that go beyond conventional HDL and LDL analysis. Berkeley HeartLab was founded as a cardiovascular reference lab that had a unique diagnostic approach but floundered largely because of the company's inability to convince cardiologists of the benefits of this new method over traditional cholesterol tests. A classic example of a re-start, new management appears to have unearthed the value in the company's proprietary testing program by recognizing the advantage in marketing Berkeley HeartLab's product as a cardiovascular diagnostic planning and disease management tool powered by web-enabled e-health technology.
Strategy Business Strategies

Screening the Screeners

A host of start-ups want to make high-volume screening the method of choice for finding drug leads and for discovering the uses for those new, mysterious targets pouring out of the genetic databases, But few of the new firms are basing their long-term plans on screening services; most are either using their systems to look for their own drugs or still evolving their business plans along with their technologies.
BioPharmaceutical Platform Technologies
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register